Merck マネジメント
マネジメント 基準チェック /34
Merckの CEO はRob Davisで、 Apr2021年に任命され、 の在任期間は 4.75年です。 の年間総報酬は$ 20.80Mで、 7.9%給与と92.1%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.018%を直接所有しており、その価値は$ 48.81M 。経営陣と取締役会の平均在任期間はそれぞれ5.3年と6.6年です。
主要情報
Rob Davis
最高経営責任者
US$20.8m
報酬総額
| CEO給与比率 | 7.91% |
| CEO在任期間 | 5yrs |
| CEOの所有権 | 0.02% |
| 経営陣の平均在職期間 | 5.3yrs |
| 取締役会の平均在任期間 | 6.6yrs |
経営陣の近況
Recent updates
Merck: Bullish Setup Into Q1 Earnings
Apr 27
Merck & Co., Inc. – Tender Offer for Terns Pharmaceuticals, Inc. (Full Acquisition Transaction)
Author: Qudus Adebara (Founder of Wane Investment House) Transaction Overview Merck & Co., Inc. (known as MSD outside the U.S. and Canada) has formally commenced a cash tender offer to acquire all outstanding shares of Terns Pharmaceuticals, Inc., following the signing of a definitive agreement on March 25, 2026.
MRK: Oncology Reorg And Pipeline Deals Will Support Higher Future P E Multiple
Analysts have lifted their Merck price targets by up to the mid double digits in recent weeks, citing higher modeled revenue growth, slightly stronger profit margins, and updated views on future P/E multiples as Merck advances its pipeline and business development moves. Analyst Commentary Recent Street research on Merck has been broadly constructive, with a cluster of price target revisions and fresh initiations pointing to confidence in the company’s execution, pipeline progress, and M&A activity.
MRK: M&A Execution Risks Around Terns And Revolution Will Restrain Future Upside
Analysts have nudged Merck's fair value estimate higher to approximately $101.30, reflecting updated assumptions for slightly stronger revenue growth, a modestly higher profit margin, and a marginally lower future P/E. This view is supported by a wave of recent price target increases into the $130 to $150 range and fresh Outperform or Overweight initiations on the stock.MRK: Pipeline Readouts And Oncology Reorg Will Support Higher Future P E Multiple
The analyst price target for Merck has been reset from $136 to $150. This reflects analysts' updated assumptions for modestly higher revenue growth, a stronger profit margin profile, and a slightly lower future P/E multiple, supported by recent research that highlights potential upside from Sac TMT, upcoming launches, and key Phase 3 readouts.MRK: Keytruda Cliff And M&A Uncertainty Will Likely Curb Long Term Upside
Analysts have lifted their Merck fair value estimate from $83.00 to about $101.04, pointing to broad price target hikes across the Street and citing confidence in upcoming product launches, Phase 3 readouts, and management's approach to the Keytruda loss of exclusivity. Analyst Commentary Recent research coverage on Merck has tilted positive, with several firms lifting price targets and starting the stock with favorable ratings.
MRK: Pipeline Readouts And Gardasil Policy Shifts Will Shape Forward Risk Balance
Analysts have lifted their Merck fair value estimate from $115.11 to $124.88, citing a higher expected future P/E, modestly higher projected revenue growth, and a series of recent price target hikes that highlight confidence in upcoming launches and data readouts. Analyst Commentary Recent Street research around Merck points to a generally constructive tone, with many firms adjusting ratings and price targets in a way that supports a higher fair value, while still flagging a few execution and policy watchpoints for investors to track.MRK: Rising Confidence In Pipeline Execution To Support Richer Future P E Multiple
Analysts have nudged our Merck fair value estimate higher to $136, reflecting a higher average price target across firms such as Scotiabank, Goldman Sachs, BMO, BofA, Citi, Wells Fargo, Bernstein, Cantor Fitzgerald, TD Cowen, and others, who cite stronger top line expectations, updated margin assumptions, and a richer future P/E multiple. Analyst Commentary Across recent research, bullish analysts are largely aligned in their view that Merck is executing well enough to support higher valuation assumptions.
The Oncology Anchor: Why Merck’s 46% Discount Defies the Keytruda Cliff
Merck’s 2026 narrative is a high-stakes drama centered on Keytruda , the world’s top-selling cancer drug. For years, the market has treated Merck like a "one-trick pony" due to the looming 2028 "patent cliff," where Keytruda will lose its legal protection and face generic competition.MRK: M&A Pipeline And Gardasil Policy Shifts Will Shape Future Risk Balance
Analysts lifted their Merck fair value estimate by about $8.50 to $115.11 per share as they factor in a higher future P/E multiple, recent price target increases from several firms, and growing confidence in the company being added to BofA's "US 1 List." Analyst Commentary Recent research on Merck gives you a mix of confidence in the company’s execution and some clear areas to watch. Here is how the current commentary breaks down.MRK: Cidara Flu Deal Will Likely Highlight Overstated Long Term Hopes
Narrative Update The analyst price target for Merck has moved higher to a range of about $105 to $135. Analysts point to sector re-ratings, recent upgrades to Outperform, and confidence in the company’s product pipeline and deal activity as key drivers of their updated views.MRK: Cidara Flu Deal Will Likely Expose Overstated Long Term Expectations
Analysts have nudged their fair value estimate for Merck higher, lifting the price target by $1 to $83 as they factor in stronger revenue growth, improved profit margins, and a lower future P/E multiple supported by recent positive research initiations and deal activity. Analyst Commentary Street research around Merck has turned more constructive in recent weeks, with several firms highlighting an improving growth outlook and a more attractive risk reward profile.Merck predicts unstoppable growth with KEYTRUDA and WINREVAIR hitting record hihs
based on Q3 resultMRK: Cidara Acquisition And Patent Overhang Will Shape Future Risk Reward Balance
Analysts have modestly raised their fair value estimate for Merck to approximately $106.62 from about $104.27 per share, citing the higher Street price target of $105, growing confidence in its infectious disease and oncology pipeline, and the view that shares remain attractively valued relative to the company's long term growth prospects. Analyst Commentary Street research on Merck continues to highlight a constructive long term outlook balanced by execution and concentration risks, with recent notes refining expectations around valuation, pipeline durability, and capital allocation.Merck (NYSE:MRK) Is Increasing Its Dividend To $0.85
Dec 02
MRK: Recent Pipeline Deals And Patent Expiry Will Shape Outlook Ahead
Analysts have raised the price target for Merck to $105 from $98, citing stronger growth prospects and a more favorable valuation because of the company’s expanding pipeline and recent strategic deals. Analyst Commentary Recent analyst commentary on Merck highlights both positive momentum and notable risks that could influence the company’s trajectory in the months ahead.Merck & Co., Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Nov 02US Investments And New Product Launches Will Shape Future Markets
Merck’s analyst price target edged up to $101.75, driven by positive sentiment around the Verona Pharma acquisition’s boost to the respiratory portfolio, ongoing digital and oncology partnerships, and stable vaccine outlook. Analyst Commentary Bullish analysts point to Merck’s $10B acquisition of Verona Pharma, seeing Verona’s Ohtu as a strategic anchor drug to expand Merck’s respiratory franchise and enhance competitiveness against major therapeutics in the space.Shareholders Can Be Confident That Merck's (NYSE:MRK) Earnings Are High Quality
Aug 12
CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Dec 31 2025 | US$21m | US$2m | US$18b |
| Sep 30 2025 | n/a | n/a | US$19b |
| Jun 30 2025 | n/a | n/a | US$16b |
| Mar 31 2025 | n/a | n/a | US$17b |
| Dec 31 2024 | US$23m | US$2m | US$17b |
| Sep 30 2024 | n/a | n/a | US$12b |
| Jun 30 2024 | n/a | n/a | US$14b |
| Mar 31 2024 | n/a | n/a | US$2b |
| Dec 31 2023 | US$20m | US$2m | US$365m |
| Sep 30 2023 | n/a | n/a | US$5b |
| Jun 30 2023 | n/a | n/a | US$3b |
| Mar 31 2023 | n/a | n/a | US$13b |
| Dec 31 2022 | US$19m | US$2m | US$15b |
| Sep 30 2022 | n/a | n/a | US$15b |
| Jun 30 2022 | n/a | n/a | US$17b |
| Mar 31 2022 | n/a | n/a | US$14b |
| Dec 31 2021 | US$14m | US$1m | US$12b |
| Sep 30 2021 | n/a | n/a | US$6b |
| Jun 30 2021 | n/a | n/a | US$4b |
| Mar 31 2021 | n/a | n/a | US$5b |
| Dec 31 2020 | US$7m | US$1m | US$5b |
| Sep 30 2020 | n/a | n/a | US$9b |
| Jun 30 2020 | n/a | n/a | US$9b |
| Mar 31 2020 | n/a | n/a | US$9b |
| Dec 31 2019 | US$8m | US$1m | US$6b |
報酬と市場: Robの 総報酬 ($USD 20.80M ) は、 US市場 ($USD 14.50M ) の同規模の企業の平均を上回っています。
報酬と収益: Robの報酬は、過去 1 年間の会社の業績と一致しています。
CEO
Rob Davis (58 yo)
5yrs
在職期間
US$20,797,845
報酬
Mr. Robert M. Davis, also known as Rob, J.D., is CEO and Director of Merck Sharp & Dohme LLC since July 1, 2021 and has been its Chairman since December 1, 2022. He is Chief Executive Officer and Director...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Chairman | 5yrs | US$20.80m | 0.018% $ 48.8m | |
| Executive VP & CFO | 5yrs | US$7.51m | 0.0037% $ 9.9m | |
| Executive VP & General Counsel | 8yrs | US$5.86m | 0.0028% $ 7.6m | |
| Executive VP & President of Merck Manufacturing Division | 16.4yrs | US$5.41m | 0.0081% $ 21.9m | |
| Executive VP & President of Merck Research Laboratories | 8.4yrs | US$8.89m | 0.0037% $ 10.1m | |
| Senior VP of Finance | 2.3yrs | データなし | 0.00033% $ 896.8k | |
| Executive VP and Chief Information & Digital Officer | no data | データなし | 0.0013% $ 3.4m | |
| Vice President of Investor Relations | 6.7yrs | データなし | データなし | |
| Executive Vice President of Strategic Access | less than a year | US$13.94m | 0.0024% $ 6.7m | |
| Executive VP & Chief Human Resources Officer | 2yrs | US$11.26m | 0.00025% $ 679.4k | |
| Executive VP & President of Merck Animal Health | 14.6yrs | US$9.10m | 0.0065% $ 17.6m | |
| Executive VP and President of Oncology & MSD International | 5.3yrs | データなし | 0.00086% $ 2.3m |
5.3yrs
平均在職期間
58yo
平均年齢
経験豊富な経営陣: MRKの経営陣は経験豊富で経験豊富です（平均在職期間は5.3年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Chairman | 4.8yrs | US$20.80m | 0.018% $ 48.8m | |
| Independent Director | 10.6yrs | US$405.00k | 0.000070% $ 190.2k | |
| Independent Director | 30.6yrs | US$365.00k | 0.00053% $ 1.4m | |
| Independent Lead Director | 18.4yrs | US$415.00k | 0.00021% $ 570.7k | |
| Independent Director | 5.9yrs | US$340.00k | 0.000040% $ 108.7k | |
| Independent Director | 3.9yrs | US$350.00k | 0.00065% $ 1.8m | |
| Independent Director | 8.1yrs | US$340.00k | 0.00012% $ 326.1k | |
| Independent Director | 5.1yrs | US$350.00k | 0% $ 0 | |
| Independent Director | 6.1yrs | US$340.00k | 0.000020% $ 54.4k | |
| Independent Director | 6.1yrs | US$385.00k | 0% $ 0 | |
| Independent Director | 10.6yrs | US$405.00k | 0% $ 0 | |
| Independent Director | 7.1yrs | US$340.00k | 0% $ 0 |
6.6yrs
平均在職期間
66.5yo
平均年齢
経験豊富なボード: MRKの 取締役会 は 経験豊富 であると考えられます ( 6.6年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/04/29 14:36 |
| 終値 | 2026/04/29 00:00 |
| 収益 | 2025/12/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Merck & Co., Inc. 21 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。49
| アナリスト | 機関 |
|---|---|
| David Toung | Argus Research Company |
| Charles Butler | Barclays |
| Emily Field | Barclays |